Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Masoprocol - GlaxoSmithKline

Drug Profile

Masoprocol - GlaxoSmithKline

Alternative Names: Actinex; CHX 100; meso-NDGA; SP 134101

Latest Information Update: 11 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Access Pharmaceuticals
  • Developer Abeona Therapeutics; Access Pharmaceuticals; GlaxoSmithKline
  • Class Anti-inflammatories; Catechols; Lignans; Small molecules
  • Mechanism of Action Lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis
  • Discontinued Cancer; Photodamage

Most Recent Events

  • 05 Dec 2001 Discontinued-Clinical for Photodamage in USA (Topical)
  • 05 Dec 2001 Discontinued-Preclinical for Cancer in USA (PO)
  • 05 Dec 2001 No-Development-Reported for Actinic keratosis in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top